http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Locating and Utilising Inherent Qualities in an Expanded Sound Palette for Solo Flute
Alice Bennett(알리스 베넷),Vincent Giles(빈센트 길레스) 한국전자음악협회 2015 에밀레 Vol.13 No.-
플루트 독주 특유의 즉흥적 음악언어를 추구하면서, 전통적이고 현대적인 연주기법의 범위를 넘어 컴퓨터를 이용한 악기의 확장이라는 영역으로 넘어가야 할 필요성을 종종 느낄 때가 있다. 이러한 이유로 알리스 베넷Alice Bennett의 창작 작품은 실용적인 사운드 팔레트를 확장시키는 새로운 전자음향적 기술을 탐색케 한다. 이 글은 빈센트 길레스Vincent Giles가 실시간으로 분광 영역 마이크로사운드 증폭 소프트웨어SDMAS(Spectral Domain Microsound Amplification Software)를 사용한 플루트 연주에 관하여 기술한다. 분광 영역 마이크로사운드 증폭 소프트웨어SDMAS는 실시간으로 입력된 소리가 특정 음량 기준점 주변 배음들의 음량을 변화시켜, 작은 소리를 상대적으로 큰 음량으로 증폭시킨다. 그 결과 들을 수 없었을 [작은] 배음들이 큰 음량의 배음들과 같이 커져, 기존의 악기 혹은 변형된 악기 음색과도 확연히 다른 음색을 얻게 된다. 이는 연주자/작곡가가 순전히 어쿠스틱 악기에서 얻을 수 있는 것과 다른 음색을 보여줄 뿐 아니라 보다 넓은 영역의 음색을 활용할 수 있게 해준다. 이는 초월적 악기의 확장형태instrument configuration에 기반한, 음향적으로 풍부하고 독특한 즉흥적 음악언어를 이끌어 낼 것이다. In the search for an idiosyncratic improvisatory language of solo flute performance, it is sometimes necessary to move beyond the scope of traditional and extended techniques into the world of instrument-extension through computers. To this end, Alice Bennett’s creative work leads to the exploration of new electroacoustic techniques, searching for ways to expand the available sonic palette. This paper documents an electronically-extended flute performance utilising Vincent Giles’ Spectral Domain Microsound Amplification Software (SDMAS) in real-time. The SDMAS amplifies soft sounds relative to loud, by real-time input, shifting the partials by amplitude around an amplitude-based pivot point. The result is that these otherwise-inaudible partials increased to audibility alongside the higher amplitude partials, drastically altering the perceived timbre of the instrument or instruments being treated. This allows the performer/composer to not only discover, but to exploit a greater range of timbres than are available to a purely acoustic instrument. These explorations lead to a sonically enriched and idiosyncratic improvisatory language based on this hyper-instrument configuration.
Giles, F J,Abruzzese, E,Rosti, G,Kim, D-W,Bhatia, R,Bosly, A,Goldberg, S,Kam, G L S,Jagasia, M,Mendrek, W,Fischer, T,Facon, T,Dü,nzinger, U,Marin, D,Mueller, M C,Shou, Y,Gallagher, N J,Larson, R A Macmillan Publishers Limited 2010 Leukemia Vol.24 No.7
Nilotinib is a highly selective Bcr–Abl inhibitor approved for imatinib-resistant chronic myeloid leukemia (CML). Nilotinib and dasatinib, a multi-targeted kinase inhibitor also approved for second-line therapy in CML, have different patterns of kinase selectivity, pharmacokinetics, and cell uptake and efflux properties, and thus patients may respond to one following failure of the other. An international phase II study of nilotinib was conducted in CML patients (39 chronic phase (CP), 21 accelerated phase (AP)) after failure of both imatinib and dasatinib. Median times from diagnosis of CP or AP to nilotinib therapy were 89 and 83 months, respectively. Complete hematological response and major cytogenetic response (MCyR) rates in CP were 79% and 43%, respectively. Of 17 evaluable patients with CML-AP, 5 (29%) had a confirmed hematological response and 2 (12%) a MCyR. The median time to progression has not yet been reached in CP patients. At 18 months 59% of patients were progression-free. Median overall survival for both populations has not been reached, and the estimated 18-month survival rate in CML-CP was 86% and that at 12 months for CML-AP was 80%. Nilotinib is an effective therapy in CML-CP and -AP following failure of both imatinib and dasatinib therapy.